| Psoriasis vulgaris
Otezla vs Ultravate
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Otezla vs Ultravate with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUltravate has a higher rate of injection site reactions vs Otezla based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ultravate but not Otezla, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Otezla
Ultravate
At A Glance
Oral
Once or twice daily
PDE4 inhibitor
Topical
Twice daily
Topical corticosteroid
Indications
- Arthritis, Psoriatic
- Psoriasis vulgaris
- Behcet Syndrome
- Psoriasis vulgaris
Dosing
Arthritis, Psoriatic, Psoriasis vulgaris, Behcet Syndrome Adults: OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily orally after 5-day titration starting at 10 mg; reduce to 30 mg once daily in severe renal impairment (OTEZLA XR not recommended in severe renal impairment).
Arthritis, Psoriatic, Psoriasis vulgaris (pediatric >=6 years) Weighing >=50 kg: OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily orally after weight-based titration; weighing 20 to <50 kg: OTEZLA 20 mg twice daily orally; reduce to once daily dosing in severe renal impairment.
Psoriasis vulgaris Apply a thin layer to affected skin twice daily for up to two weeks; total dosage should not exceed 50 grams (50 ml) per week.
Contraindications
- Known hypersensitivity to apremilast or to any of the excipients in the formulation
—
Adverse Reactions
Most common (>=2%) Diarrhea, nausea, headache, upper respiratory tract infection, vomiting, abdominal pain upper, nasopharyngitis
Serious Hypersensitivity, depression, weight decrease, severe worsening of psoriasis (rebound)
Most common (>=1%) Telangiectasia, application site atrophy, headache
Less common (<1%, >0.1%) Application site discoloration, herpes zoster, influenza, nasopharyngitis, otitis media acute, throat infection, wound, increased blood pressure
Pharmacology
Apremilast is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP); PDE4 inhibition increases intracellular cAMP levels and reduces pro-inflammatory cytokines including IL-17, IL-22, and TNF-alpha in blood and skin.
Halobetasol propionate is a super-high potency topical corticosteroid that plays a role in cellular signaling, immune function, inflammation, and protein regulation; the precise mechanism of action in plaque psoriasis is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Otezla
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (9/12)
Ultravate
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Otezla
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (2/8) · Qty limit (8/8)
Ultravate
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Otezla
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Ultravate
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAmgen Safety Net Foundation: Otezla
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Ultravate.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OtezlaView full Otezla profile
UltravateView full Ultravate profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.